Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: Association with liver histology


Colak Y., Senates E., Ozturk O., YILMAZ Y., Zemheri E., Yilmaz Enc F., ...Daha Fazla

European Journal of Gastroenterology and Hepatology, cilt.24, sa.3, ss.255-261, 2012 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 3
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1097/meg.0b013e32834e8041
  • Dergi Adı: European Journal of Gastroenterology and Hepatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.255-261
  • Anahtar Kelimeler: fatty liver, insulin-like growth factor-I, insulin-like growth factor binding protein-5
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objective: In this study, we aimed to investigate the relationship between the histological features of nonalcoholic fatty liver disease (NAFLD) and serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-5 (IGFBP-5) to determine the usefulness of this relationship in clinical practice. Materials and Methods: Serum samples were collected from 92 patients with biopsy-proven NAFLD and 51 healthy controls and serum levels of IGF-1 and IGFBP-5 were assayed by enzyme-linked immunosorbent assay. RESULT: Serum IGFBP-5 levels were correlated with liver steatosis, fibrosis, and nonalcoholic steatohepatitis scores. IGF-1 levels were significantly decreased in patients with moderate-to-severe fibrosis compared with patients with no or mild fibrosis. Conclusion: Serum IGFBP-5 levels may be useful to differentiate both advanced fibrosis and definite nonalcoholic steatohepatitis from other NAFLD groups. Also, serum IGF-1 levels may be useful to differentiate advanced fibrosis in patients with NAFLD. © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.